sees fy adjusted earnings per diluted share $23.55 to $3.95.
sees fy adjusted earnings per share $23.55 to $23,95 excluding items.
q3 adjusted earnings per share $6.15.
sees fy adjusted earnings per diluted share accretion of approximately $0.10.
sees fy adjusted earnings per diluted share $2.99 to $3.59.
q3 adjusted earnings per share $1.10.
q3 adjusted earnings per share $6.15.
sees fy 2021 adjusted earnings per share $22.35 to $21.95 excluding items.
expects to return approximately $3.5 billion to shareholders through share repurchases in fiscal 2022.
sees fy 2022 adjusted earnings per share $1.50 to $2.00.
sees fy adjusted earnings per diluted share accretion of $0.10.
sees fy 2021 revenue growth of 32% to 36%.
sees 2021 u.s. pharmaceutical segment revenue to increase 8% to 11% year-over-year.
sees fy adjusted earnings per share $0.85 to $1.05.
sees q4 sales of u.k. business to be approximately $1.5 billion.
qtrly gaap-only after-tax charge of $829 million related to sale of retail and distribution businesses in u.k. to account for remeasurement of net assets to lower carrying amount of fair value less cost to sell.
